Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1321

Shown on this page

Current sort

Live official records

Conditions: Multiple Myeloma
Interventions: Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 67
States / cities: Gilbert, Arizona • Tucson, Arizona • Clovis, California + 53 more

Conditions: ALD - Alcoholic Liver Disease
Interventions: Blood draw; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Kidney Injury
Interventions: Study Physician/Advance Practice Provider, Nurse Navigator, Pharmacist, Patient Education; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 2,145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Birmingham, Alabama • New Haven, Connecticut • Weston, Florida + 3 more

Conditions: Mitral Regurgitation
Interventions: CardioMech MVRS; Device
Lead sponsor: CardioMech AS; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 12
States / cities: Thousand Oaks, California • Evanston, Illinois • Wichita, Kansas + 9 more

Conditions: Bladder Cancer
Interventions: TAR-200, Cetrelimab, BCG Vesiculture; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 51
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Long Beach, California + 42 more

Conditions: Metastatic Ewing Sarcoma
Interventions: Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, Actinomycin, Irinotecan, Cabozantinib, Topotecan, Temozolomide, Etoposide, Liposomal doxorubicin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 1 Year and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 17 more

Conditions: Severe Tricuspid Regurgitation
Interventions: Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System, Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2041
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • Thousand Oaks, California + 9 more

Conditions: Multiple Myeloma
Interventions: Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone, Bortezomib; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 49
States / cities: Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more

Conditions: Arthroplasty, Replacement, Shoulder
Interventions: Reverse Total Shoulder; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 22 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: Atlantis, Florida • Waltham, Massachusetts • Grand Rapids, Michigan + 12 more

Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
Interventions: GALAD, Liver Ultrasound with or without AFP; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 19
States / cities: Los Angeles, California • Redwood City, California • Roseville, California + 14 more

Conditions: Multiple Myeloma
Interventions: JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib, Dexamethasone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 33
States / cities: San Diego, California • San Francisco, California • New Haven, Connecticut + 27 more

Conditions: Generalized Anxiety Disorder
Interventions: Placebo, DT120; Other · Drug
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more

About this Cleveland Clinic institution page

What this page lists: ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Cleveland Clinic

Filter and sort this campus

Live official records

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Comparison of ALD, NASH, and Healthy Control Patients

A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial

EFS of the CardioMech MVRS

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

INHANCE Stemless Reverse Shoulder IDE

National Liver Cancer Screening Trial

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

About this Cleveland Clinic institution page